Marketing class actions: a new frontier for medical products

By Toby Biddle (AU) and Helen Macpherson (AU) on June 5, 2017 Posted in International

A new type of product claim is emerging in the Australian class action market; one which has been part of the US class action landscape for many years. Unlike previous product class actions where the safety of the product was typically in issue, the new product claims focus on statements/ representations made in the marketing … Continue reading

Consumer claims under Canada’s patent regime foreclosed

By Randy Sutton (CA) on February 1, 2016 Posted in International

In Low v. Pfizer Canada Inc. the British Columbia Court of Appeal accepted Pfizer’s argument that the Canadian patent regulatory regime does not provide the basis for a civil action by consumers based on alleged breaches of the patent regime. The Court found, in relation to a claim pertaining to Pfizer’s Viagra, that the patent … Continue reading

Pharma in Focus – reforming class actions for pharmaceutical claims

By Toby Biddle (AU) on March 10, 2015 Posted in Enforcement, International

The issue of reforming class actions for pharmaceutical claims is highlighted in this opinion piece by Partner Toby Biddle on the Vioxx litigation. This article was originally published by Pharma In Focus and is reproduced with permission. Vioxx case highlights class action difficulties A decade of litigation over MSD’s Vioxx (rofecoxib) may prompt reform around … Continue reading